AbbVie Challenges Medicare Price Controls on Botox, Citing Plasma-Derived Product Exemption
核心洞察
AbbVie (搜索) filed a federal lawsuit against HHS challenging the inclusion of Botox in Medicare's drug price negotiation program under the Inflation Reduction Act.
The company argues Botox qualifies for statutory exemption as a plasma-derived product since approximately one-third contains human serum albumin from donated plasma.
AbbVie (搜索) claims CMS exceeded its authority by selecting Botox for the third cycle of price negotiations set to take effect in 2028.
AbbVie (搜索) Inc. has filed a federal lawsuit challenging the Centers for Medicare & Medicaid Services' decision to include Botox in the Medicare Drug Price Negotiation Program, arguing the drug should be exempt under statutory exclusions established by Congress in the Inflation Reduction Act.
The pharmaceutical company filed the complaint Wednesday in the US District Court for the District of Columbia, naming HHS, Health Secretary Robert F. Kennedy Jr., CMS, and CMS Administrator Mehmet Oz as defendants. Botox was selected as one of 15 drugs for the third cycle of price negotiations, with new prices set to take effect in 2028.
Plasma-Derived Product Exemption Claim
AbbVie (搜索)'s central argument centers on Botox's classification as a plasma-derived product, which Congress specifically excluded from Medicare price controls under the IRA. The company states that approximately one-third of Botox consists of human serum albumin (HSA), a protein derived from human blood plasma that is essential for the drug's safety and effectiveness.
"Unlike previous challenges related to the IRA, this lawsuit is the first that arises from CMS's violation of one of those express statutory exclusions established by Congress: namely, the IRA's exclusion of 'plasma-derived products' from price controls," AbbVie (搜索) said in its complaint.
The CMS typically excludes biological products that come from human whole blood or plasma from price negotiations. Since HSA is sourced from donated human plasma, AbbVie (搜索) argues that Botox meets the legal definition of a plasma-derived product and "undoubtedly falls within that exclusion."
Constitutional and Legal Challenges
Beyond the statutory exemption argument, AbbVie (搜索) alleges multiple constitutional violations. The company claims the pricing requirements force it to sell Botox to Medicare beneficiaries at "confiscatory prices," violating the Fifth Amendment's takings clause by requiring it to turn over the product without just compensation.
The lawsuit also raises First Amendment concerns, arguing that the policy compels AbbVie (搜索) to express an "untrue statement" by characterizing the negotiated price as "fair." Additionally, the company alleges violations of the Administrative Procedure Act and due process protections.
AbbVie (搜索) contends that failing to comply with the pricing requirements could result in significant tax penalties and potential exclusion from federal healthcare programs.
Botox's Medical Applications and Revenue Impact
While Botox is widely recognized for cosmetic wrinkle reduction, the drug treats several medical conditions including chronic migraines (搜索), muscle spasms (搜索), eye and neck movement disorders, and incontinence (搜索). In 2023, Botox generated just over 10% of AbbVie (搜索)'s $61.16 billion in total revenue, with therapeutic uses accounting for approximately 6% of the company's revenue.
Broader Industry Legal Challenge
This lawsuit joins a series of legal challenges from pharmaceutical manufacturers targeting the Medicare drug price negotiation program. Previous lawsuits from the industry have largely been rejected by federal courts. Several pharmaceutical giants including AstraZeneca Plc, Boehringer Ingelheim Pharmaceuticals, and Bristol Myers Squibb (搜索) Co. are currently urging the US Supreme Court to review the program.
AbbVie (搜索) describes this case as distinct from previous challenges, as it specifically alleges that CMS violated a statutory exclusion rather than challenging the program's overall constitutionality. Paul, Weiss, Rifkind, Wharton & Garrison LLP represents AbbVie in the litigation.